Mauna Kea Technologies Announces Global Expansion of Cellvizio LAB Distribution Network in Pre-Clinical Research

Regulatory News:

Mauna Kea Technologies (Paris:MKEA) (NYSE Euronext: MKEA, FR0010609263), leader in the optical biopsy market and developer of Cellvizio®, the fastest way to see cancer, has entered several distribution agreements for its line of Cellvizio LAB products, including the Cellvizio Dual Band, for pre-clinical research.

With new partnerships in place in North America, Taiwan, Italy, Israel and Eastern Europe, Cellvizio LAB is now actively marketed to research laboratories in more than 25 countries.

Quorum Technologies Inc., a North American leader in confocal microscopy and advanced in vivo imaging techniques, will distribute the full range of Cellvizio LAB systems and products, including the Cellvizio Dual Band, to research laboratories in the United States and exclusively in Canada.

"Cellvizio LAB represents a major step forward in the evolution of microscopic imaging, which has evolved from in vitro views of fixed tissue to long-term observation of cultured cells and now to a high-resolution view of cells in the very best environmental system available, the living animal,” said Jeff Butler, confocal imaging specialist at Quorum Technologies. "With Cellvizio LAB added to our portfolio, we are able to offer our customers the most comprehensive set of tools and software platforms to support the in vitro and in vivo imaging needs of scientific and medical researchers.”

The Cellvizio Dual Band is Mauna Kea Technologies’ latest innovation in animal imaging that provides structural and functional information about living tissues inside the animal’s body in real time and in several colors.

Mauna Kea Technologies also announced key Cellvizio LAB distribution partnerships with Cold Spring Biotech Corp. in Taiwan; Crisel Instruments in Italy; Biotech Europe in Central and Eastern Europe; and Merkel Technologies in Israel.

"We selected these new distribution partners for their high-quality customer networks in high-growth markets that include top-tier research laboratories, pharmaceutical companies and some of the most innovative biotech companies in the industry,” commented Sacha Loiseau, CEO of Mauna Kea Technologies. "We’re so pleased that much of the global scientific community now has access to Cellvizio Dual Band technology which will continue to be the key driver of our pre-clinical sales.”

Mauna Kea Technologies shares are currently covered by sector analysts at Gilbert Dupont, DSF Markets, Société Générale and Kempen & Co.

About Mauna Kea Technologies

Mauna Kea Technologies is a global medical device company dedicated to the advent of optical biopsy. The company researches, develops and markets innovative tools to visualize and detect cellular abnormalities during endoscopic procedures. Its flagship product, Cellvizio®, a probe-based Confocal Laser Endomicroscopy (pCLE) system, provides physicians and researchers high-resolution cellular views of tissue inside the body. Large, international, multicenter clinical trials have demonstrated Cellvizio's ability to help physicians more accurately detect early forms of disease and make treatment decisions immediately. Designed to improve patient outcomes and reduce costs within a hospital, Cellvizio can be used with almost any endoscope. Cellvizio has 510(k) clearance from the U.S. Food and Drug Administration and the European CE-Mark for use in the GI tract, biliary and pancreatic ducts, lungs and during needle-based procedures.
For more information on Mauna Kea Technologies, visit www.maunakeatech.com

Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe to, or a solicitation of an offer to buy or subscribe to, shares in Mauna Kea Technologies ("the Company") in any country. This press release contains forward-looking statements that relate to the Company’s objectives. Such forward-looking statements are based solely on the current expectations and assumptions of the Company’s management and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company’s products, new products or technological developments introduced by competitors, and risks associated with managing growth. Unfavorable developments in connection with these and other risks and uncertainties described, in particular, in the Company’s prospectus prepared in connection with its IPO and on which the French Autorité des marches financiers ("AMF”) granted its visa number 11-236 on June 230, 2011, could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.